Additional file 3 of Peripheral myeloid-derived suppressor cells are good biomarkers of the efficacy of fingolimod in multiple sclerosis

Celia Camacho-Toledano, Isabel Machín-Díaz, Leticia Calahorra, María Cabañas-Cotillas, David Otaegui, Tamara Castillo-Triviño, Luisa María Villar, Lucienne Costa-Frossard, Manuel Comabella, Luciana Midaglia, José Manuel García-Domínguez, Jennifer García-Arocha, María Cristina Ortega & Diego Clemente
Additional file 3: Table S3. Correlations between M-MDSCs and clinical parameters after 12 months of fingolimod treatment.
This data repository is not currently reporting usage information. For information on how your repository can submit usage information, please see our documentation.